Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-12892 |
Brand: | MCE |
CAS: | 1259484-97-3 |
MDL | - |
---|---|
Molecular Weight | 394.42 |
Molecular Formula | C21H22N4O4 |
SMILES | O=C(C1=CC(C2=CC=C(OC)C=C2)=NN1)N/N=C(C3=CC=C(OC)C(OC)=C3)\C |
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC 50 concentrations ranging from 1.8 to 0.1 μM in both drug sensitive and multi-drug resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines [1] [2] .
SKI-178 (5 μM; 24 hours)-induced apoptotic cell death correlates with prolonged Bcl-2 phosphorylation [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Apoptosis Analysis [1]
Cell Line: | HL-60 cells |
Concentration: | 5 μM |
Incubation Time: | 24 hours |
Result: | JNK activity (indicated by phosphorylation at Thr183/Tyr185) increased in a time-dependent manner starting as early as 2 hours continued to increase for at least 24 hours. There was a concomitant increase in apoptotic cell death indicated by the cleavage of caspase-7. Bcl-2 phosphorylation at Ser70 increased with time in response to SKI-178 treatment, reaching maximal levels at 8 hours, which was consistent with the timing of caspase-7 activation. |
SKI-178 (20 mg/kg; retro-orbital injection under isoflurane anesthesia) inhibits leukemic progression in the MLL-AF9 model [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | MLL-AF9 mouse model (leukemic mice) [3] |
Dosage: | 20 mg/kg |
Administration: | Retro-orbital injection under isoflurane anesthesia; three times per week for 1 and 3 weeks |
Result: | White blood cell (WBC) counts decreased from their initial 104 cells/μL levels and continued to decline after 3 weeks of treatment until they reached normal levels (~4×103 cells/μL). |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 50 mg/mL ( 126.77 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.5354 mL | 12.6768 mL | 25.3537 mL |
5 mM | 0.5071 mL | 2.5354 mL | 5.0707 mL |
10 mM | 0.2535 mL | 1.2677 mL | 2.5354 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.